We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Dr Emmanuelle Charpentier is the founder of CRISPR Therapeutics, and one of the scientists credited with its discovery. However Charpentier is competing with rivals and former colleagues who have ...

The JV will be led by Dr Axel Bouchon, head of the BLSC, on an interim basis as CEO, while Dr Rodger Novak, CEO and co-founder of CRISPR Therapeutics, will serve as the interim chairman of the ...

Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ ...

CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The firm had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 ...

Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day.

Scribe Therapeutics is revolutionizing the development of optimized in vivo CRISPR-based genetic medicines ... more effective genetic therapies. Co-founded by Nobel Prize winner Jennifer Doudna ...